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Who to Test for Hepatitis C Virus in the 
Middle East and North Africa?: Pooled 
Analyses of 2,500 Prevalence Measures, 
Including 49 Million Tests
Hiam Chemaitelly,1 Sarwat Mahmud,1 Silva P. Kouyoumjian,1 Zaina Al-Kanaani,1 Joumana G. Hermez,2 and  
Laith J. Abu-Raddad 1,3,4
Expanding hepatitis C virus (HCV) treatment coverage is challenged by limited testing and diagnosis. This study as-
sessed the risk of exposure, for the Middle East and North Africa, by population, yields of testing, and program ef-
ficiency of testing strategies. A standardized and systematically assembled database of 2,542 HCV antibody prevalence 
studies on 49 million individuals was analyzed. Random effects meta-analyses were conducted to estimate pooled 
measures for risk of exposure, risk ratio (RR) of exposure, and yields of testing. Program expansion path curves were 
calculated to assess program efficiency. Countries clustered into two patterns: generalized versus concentrated epidem-
ics. In generalized epidemics (Egypt and Pakistan) relative to general populations, RR of exposure was 6.8 for people 
who inject drugs (PWID), 6.7 for populations with liver conditions, and 5.0 for populations with high-risk health care 
exposures. In concentrated epidemics (remaining countries), corresponding RRs were 97.2, 45.1, and 22.2, respectively. 
In generalized epidemics, the number of tests needed to identify a chronic infection was 2.5 for PWID, 2.4 for popu-
lations with liver conditions, 2.7 for populations with high-risk health care exposures, and 14.2 for general popula-
tions. In concentrated epidemics, corresponding numbers were 2.8, 8.6, 5.1, and 222.2, respectively. Program expansion 
path curves demonstrated major gains in program efficiency by targeting specific populations. Risk of exposure varies 
immensely by population and shows a distinctive hierarchy, particularly in concentrated epidemics. Testing strategies 
can be much more efficient through population prioritization by risk of exposure. General population testing is not 
programmatically efficient in concentrated epidemics. (Hepatology Communications 2019;3:325-339).
Abbreviations: CI, confidence interval; GHSS, Global Health Sector Strategy on Viral Hepatitis, 2016-2021; HCV, hepatitis C virus; HIV, 
human immunodeficiency virus; LMICs, low- and middle-income countries; MENA, Middle East and North Africa; PWID, people who inject 
drugs; RR, relative risk; UAE, United Arab Emirates; WHO, World Health Organization.
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V iral hepatitis is the seventh leading cause of mortality globally.(1) A third of this mortal-ity is attributed to hepatitis C virus (HCV), 
a major cause of acute viral hepatitis and liver fibro-
sis, cirrhosis, and cancer.(1-4) In the Middle East and 
North Africa (MENA), HCV accounts for two thirds 
of viral hepatitis mortality and disability-adjusted 
life years.(1,4) Although exposure to HCV infection 
has been estimated at 1%-3% in most countries,(2,5) 
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disproportionate infection levels are found in the 
MENA countries.(2,3,5,6) In this region, antibody 
prevalence has reached high levels in populous coun-
tries, particularly in Egypt and Pakistan, at 10.0%(7-
10) and 4.8%,(11-13) respectively.
It has been recently estimated that 71 million peo-
ple are chronically infected with HCV worldwide, 
including 15 million in the MENA region, which 
is the most affected.(1,4) Most of those infected, 
however, are unaware of their infection; infection 
is mostly asymptomatic until advanced stages of 
disease.(14) With the breakthroughs in treatment, 
namely the development of highly efficacious oral 
direct-acting antivirals (DAAs),(15-17) and the rapid 
drop in treatment regimen costs from more than 
$80,000 to only $100 in some resource-limited 
countries, such as Egypt(18,19) and Pakistan,(20,21) 
availability and accessibility of effective treat-
ment have been rendered surmountable challenges. 
Nonetheless, diagnosis of those infected has become 
a global challenge to address this disease burden and 
to control transmission.
In the context of this historical opportunity to 
cure HCV infections, achieve large reductions in 
disease burden, and even eliminate this blood-borne 
virus as a public health concern, the World Health 
Organization (WHO) formulated the Global Health 
Sector Strategy on Viral Hepatitis, 2016-2021 
(GHSS)(22) and established service coverage tar-
gets to eliminate HCV as a public health threat by 
2030.(22,23) The strategy specifically calls for scaling 
up testing and treatment to achieve by 2030 target 
coverage levels of 90% for HCV diagnosis, 80% for 
HCV treatment, as well as 80% reduction in HCV 
incidence.(4,22,23)
These ambitious targets are challenged by the 
logistics of establishing programs that can achieve 
such coverage targets, more so in low- and middle-in-
come countries (LMICs). The cost for testing, for 
example, remains a challenge despite the amendment 
of the screening algorithm from a three- to two-step 
approach.(24,25) The latter consists of a single anti-
body detection test while discontinuing further con-
firmatory testing, followed by RNA testing to detect 
chronic infection.(24,25)
With the identification of those infected becom-
ing probably the leading challenge for HCV response 
in the MENA region and elsewhere, we aimed to 
address who should be tested for HCV so that test 
and treat programs could be scaled up efficiently and 
effectively, targeting those most likely to be carri-
ers. Against a dearth of studies on HCV testing in 
LMICs,(26,27) we addressed specific questions for the 
MENA region: (1) Which populations are at higher 
risk of having been exposed and therefore should be 
tested? (2) What are the yields of a testing program 
targeting different populations? (3) How can testing 
programs be efficiently expanded? The yield of a test-
ing program is defined here as the number of indi-
viduals needed to be tested to identify one chronically 
infected individual.(28)
We addressed these questions through an in-depth 
quantitative assessment of a standardized and system-
atically assembled database of 2,542 HCV antibody 
prevalence studies on more than 49 million individu-
als across 24 countries, which to our knowledge is the 
largest HCV epidemiology database worldwide. Our 
overarching aim was to provide the scientific evidence 
necessary to inform policy and strategic prioritiza-
tion and resource allocation of programming across 
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MENA countries, the majority of which fall under 
the umbrella of LMICs. The criticality of this analysis 
arises from the fact that ill-informed and inefficient 
testing could have a serious and crippling budgetary 
impact and may diminish the political enthusiasm to 
scale up testing and treatment.(26)
Participants and Methods
Data souRCes
The source of data was the MENA HCV 
Epidemiology Synthesis Project database, a compre-
hensive database of HCV epidemiologic measures.(29) 
The database includes 2,542 unique antibody preva-
lence studies from MENA countries based on testing 
49,021,211 individuals, among whom 461,965 were 
antibody positive.
The database was populated through a series of 
systematic literature reviews covering every MENA 
country: Afghanistan,(30) Algeria,(31) Bahrain,(32) 
Djibouti,(33) Egypt,(9,10) Iran,(34) Iraq,(35) Jordan,(35) 
Kuwait,(32) Lebanon,(35) Libya,(31) Mauritania,(31) 
Morocco,(31) Oman,(32) Pakistan,(13) Palestine,(35) 
Qatar,(32) Saudi Arabia,(32) Somalia,(33) Sudan,(33) 
Syria,(35) Tunisia,(31) the United Arab Emirates 
(UAE),(32) and Yemen.(33) These reviews were 
informed by the Cochrane Collaboration Handbook 
guidelines,(36) and the findings were reported using 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines.(37)
Data sources for these reviews included international 
scientific databases (PubMed and Embase), regional- 
and country-level scientific databases (WHO Index 
Medicus for the Eastern Mediterranean Region, Iraqi 
Academic Scientific Journals’ database, and Iran’s 
Scientific Information Database, among others), rel-
evant country-level (Ministries of Health and Civil 
Society) and international organizations’ reports and 
routine data, the MENA human immunodeficiency 
virus (HIV)/acquired immune deficiency syndrome 
Epidemiology Synthesis Project database,(38,39) and 
abstract archives of nonindexed international scientific 
conferences.
Search criteria were broad, combining medical 
index terms (MeSH/Emtree) exploded to cover all 
subheadings and free text terms for HCV and rel-
evant country names. No language restrictions were 
used. Data from non-English articles were extracted 
by native speakers. Records were considered for anal-
ysis if published after 1989, the year when HCV was 
first characterized.(40,41)
The database also incorporates recent updates to 
these systematic reviews as well as unpublished coun-
try-level routine data and thus is the most complete 
database for HCV infection in the MENA region. All 
HCV prevalence measures were subject to a detailed 
quality assessment as described(9,10,13,30-35,42) and as 
informed by the Cochrane Collaboration Handbook 
guidelines.(36)
epiDemiologiC 
ClassiFiCation
Prevalence studies were classified into six epidemi-
ologic population categories based on an established 
population classification for the perceived risk of 
being exposed to HCV infection(6,9,10,13,30-35,42-45) and 
as informed by existing literature.(3,5,46) Based on this 
classification, prisoners were considered a population 
at intermediate risk because they can be exposed to 
HCV through practices such as tattooing, piercing, 
or anal sex. Importantly, a proportion of prisoners 
also could be people who inject drugs (PWID), with 
this proportion varying immensely from one setting 
to another.(42,47) Patients with HIV were classified 
based on the status of the HIV epidemic in each 
country. Specifically, they were considered at high 
risk whenever the epidemic was dominated by iatro-
genic transmission (injecting drug networks, such as 
in Iran, Libya, and Pakistan)(47) and at intermediate 
risk whenever the epidemic was dominated by sexual 
transmission.(48,49)
Definitions and examples illustrating each of these 
population categories are included in Fig. 1, with fur-
ther details found in previous studies.(6,9,10,13,30-35,43-45) 
The same definitions were applied to all studies in all 
countries. All studies among PWID were for cur-
rent PWID, not ex-PWID who are no longer inject-
ing. Population- and country-mixed samples were 
excluded from further analysis. Consequently, the 
analyses included a total of 2,521 prevalence studies 
on 48,931,779 individuals, among whom 459,598 
individuals were antibody positive (Table 1).
The HCV epidemic in each country was clas-
sified as either generalized or concentrated. In the 
absence of a working definition in the literature and 
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in light of a broad understanding of HCV epidemi-
ology,(6,9,10,13,30-35,43-45,50-55) we defined a generalized 
epidemic as a pooled mean HCV antibody prev-
alence in the general population being ≥3% and a 
concentrated epidemic as a pooled mean prevalence 
being <3%.
QuantitatiVe analysis
Risk of Having Been exposed to HCV 
infection
We assumed that the risk (likelihood) of having 
been exposed to HCV in a population is equal to the 
Fig. 1. Population epidemiologic classification based on the perceived risk of having been exposed to HCV.
taBle 1. summaRy oF HCV pReValenCe stuDies aCRoss tHe mena CountRies, tHat WeRe 
inCluDeD in analysis, stRatiFieD By population epiDemiologiC CategoRy
Population
Number of HCV 
Prevalence Measures
Number of Individuals 
Tested for HCV
Number of HCV Antibody-Positive 
Individuals
People who inject drugs 108 44,094 17,004
Populations with high-risk health care exposures 440 123,249 45,034
Populations at intermediate risk 340 290,721 31,204
General populations 1,182 48,245,780 299,489
Populations with liver conditions 245 131,343 51,069
Special clinical populations 206 96,592 15,798
All populations 2,521 48,931,779 459,598
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mean HCV antibody prevalence in that population. 
Estimate of the risk of having been exposed to HCV 
for each epidemiologic population was calculated by 
pooling prevalence measures belonging to that popu-
lation category (Fig. 1). Pooling was conducted using 
DerSimonian–Laird random effects models with 
inverse variance weighting.(56) These meta-analyses 
were performed at the country, epidemic (generalized/
concentrated), and regional levels. The 95% confidence 
intervals (CIs) were further reported. Meta-analyses 
were conducted in R version 3.4.1(57) using the meta 
package.(58)
Risk Ratios of Having Been exposed to 
HCV infection
For each country, we used the combined sample of 
all prevalence studies for each epidemiologic popula-
tion to calculate the risk ratio (RR) of having been 
exposed to HCV infection in that specific population 
relative to every other population. Specifically, we 
divided the pooled proportion of HCV antibody-pos-
itive individuals for each country for a specific epide-
miologic population by that of every other population.
To estimate the pooled mean RR (at the regional 
level) of having been exposed to HCV for any two 
epidemiologic populations as well as in the subsets of 
countries with generalized versus concentrated epi-
demics, we pooled the country-specific RRs using 
DerSimonian–Laird random effects meta-analyses 
with inverse variance weighting.(56) The 95% CIs were 
further reported.
Meta-analyses were conducted in Stata/SE version 
14(59) using the metan package.
yields of HCV testing programs
Country-specific, epidemic-specific, and regional 
estimates for the yields (number of individuals needed 
to be tested to identify one chronically infected indi-
vidual) of potential testing programs targeting the dif-
ferent epidemiologic populations were derived using 
the inverse of the pooled mean risk of having been 
exposed to HCV.(28) In this derivation, a spontaneous 
clearance rate of 25% was assumed based on estimates 
from prospective cohort studies.(60,61) Of note, a recent 
modeling study suggested that the HCV spontaneous 
clearance rate may have been underestimated in pro-
spective cohort studies.(62)
program efficiency and testing 
program expansion path Curves
Program expansion path curves were also calculated 
for the yields in countries with generalized versus 
concentrated epidemics. A program expansion path 
curve is a metric of program efficiency that delineates, 
in a graphical representation, how a program should 
efficiently be expanded.(63,64) This metric as applied 
here describes the growth in the number of individ-
uals needed to be tested to identify one chronically 
infected individual as the testing program is expanded 
one population at a time.
The hierarchy of population expansion was based 
on the hierarchy of the yield; that is, the expansion 
path curve was generated by first targeting the pop-
ulation with the lowest number of individuals needed 
to be tested to identify a case, then adding the popu-
lation with the second lowest number, and so forth, up 
to the population with the highest number of individ-
uals needed to be tested to identify a case.
sensitiVity analyses
Estimates for the risk of having been exposed to 
HCV were pooled by applying weights factoring the 
population size of each country as derived from the 
United Nations World Population Prospects data-
base.(65) The impact of this weighting strategy on the 
RRs of having been exposed to HCV infection and on 
the yields of a testing program were further assessed.
Sensitivity analysis comparing estimates based on 
population-based surveys to those using all measures 
was further conducted.
Results
The HCV prevalence measures included in analy-
sis stratified by population epidemiologic category are 
summarized in Table 1.
RisK oF HaVing Been eXposeD
Results of the pooled analyses for the risk of having 
been exposed to HCV are presented in Table 2. For 
PWID, the risk ranged between 25.0% in Lebanon 
and 94.2% in Libya, with a median of 52.6%. For 
countries with a generalized epidemic, it was 54.2%, 
CHemaitelly et al. Hepatology CommuniCations, march 2019
330
taBle 2. pooleD estimates FoR tHe RisK oF HaVing Been eXposeD to HCV aCRoss mena 
CountRies, stRatiFieD By population epiDemiologiC CategoRy
Country
Mean Risk of Having Been Exposed to HCV
People Who Inject 
Drugs % (95% CI)
Populations With 
High-Risk Health 
Care Exposures % 
(95% CI)
Populations at 
Intermediate Risk 
% (95% CI)
General 
Populations % 
(95% CI)
Populations With 
Liver Conditions % 
(95% CI)
Special Clinical 
Populations %  
(95% CI)
Afghanistan 32.87 (25.17-41.07) NA* 2.34 (1.29-3.67) 0.74 (0.57-0.93) NA* NA*
Algeria NA* 17.86 (11.25-25.55) 4.96 (0.00-17.31) 0.13 (0.03-0.29) NA* 69.7† (65.05-74.09)
Bahrain NA* 55.74 (26.35-83.12) NA* NA* NA* 8.19 (0.00-29.70)
Djibouti NA* NA* NA* 0.28 (0.21-0.37) 0† (0.00-0.06) NA*
Egypt 63.00† (52.76-72.44) 55.44 (49.12-61.67) 13.99 (10.09-18.38) 11.83 (11.14-12.53) 58.81 (51.46-65.97) 38.67 (32.22-45.33)
Iran 52.17 (46.88-57.43) 24.80 (20.39-29.48) 6.17 (3.44-9.58) 0.29 (0.21-0.37) 7.52 (4.34-11.43) 2.65 (1.82-3.61)
Iraq NA* 19.75 (15.11-24.82) 1.26 (0.68-1.98) 0.18 (0.13-0.25) 6.97 (3.86-10.84) 2.77 (1.79-3.92)
Jordan NA* 33.17 (25.27-41.57) 0.66† (0.02-3.61) 0.15 (0.07-0.25) NA* 40.56† (32.43-49.08)
Kuwait NA* 18.74 (5.73-36.88) 5.34 (0.52-14.33) 1.37 (0.05-4.05) 5.88 (0.00-23.25) 60.60† (42.14-77.09)
Lebanon 25.03 (4.40-54.51) 7.39 (4.16-11.38) 2.16 (0.26-5.36) 0.15 (0.06-0.25) 19.57† (12.03-29.15) 0.00 (0.00-0.76)
Libya 94.20† (91.46-96.72) 27.26 (18.85-36.57) 5.38 (1.74-10.73) 1.59 (1.44-1.76) NA* 37.79 (24.84-51.69)
Mauritania NA* NA* NA* 1.10† (0.31-2.91) NA* NA*
Morocco 52.97 (33.11-72.35) 38.34 (18.69-60.15) 3.88 (2.32-5.79) 0.65 (0.47-0.86) 37.94 (3.70-81.56) 9.02 (3.87-15.87)
Oman 48.05† (43.64-52.47) 33.71 (20.83-47.93) NA* 0.75 (0.60-0.92) NA* 8.80 (0.92-22.66)
Pakistan 53.63 (36.21-70.62) 32.84 (25.34-40.78) 12.94 (10.85-15.18) 6.15 (5.68-6.65) 55.10 (48.19-61.91) 24.56 (12.58-38.91)
Palestine 41.58 (36.24-47.02) 10.34 (5.64-16.17) NA* 0.24 (0.18-0.30) NA* NA*
Qatar NA* 44.61† (35.90-53.58) NA* 1.90 (1.09-2.93) 33.08 (18.48-49.47) 9.00† (4.19-16.40)
Saudi Arabia 58.67 (18.17-93.10) 46.74 (43.12-50.37) 8.95 (4.01-15.49) 0.75 (0.68-0.82) 27.23 (20.96-33.97) 11.16 (7.86-14.92)
Somalia NA* NA* 1.71 (0.10-4.56) 1.07 (0.32-2.15) 20.18 (4.52-42.62) NA*
Sudan NA* 18.42 (8.42-31.07) 0.70 (0.29-1.24) 1.36 (0.63-2.31) 7.32 (1.26-17.0) 5.21 (0-17.08)
Syria 39.62 (7.03-78.46) 43.53 (26.34-61.56) 2.98 (1.77-4.45) 0.41 (0.36-0.47) 1.04† (0.13-3.69) 48.00† (27.80-68.69)
Tunisia 85.61† (78.44-91.11) 25.05 (20.24-30.17) 6.30 (1.31-14.38) 0.60 (0.44-0.79) 22.42 (10.02-37.78) 10.69 (0.28-30.97)
United Arab 
Emirates
NA* 24.00† (19.35-30.09) 15.74 (3.58-33.94) 2.02 (1.25-2.96) NA* NA*
Yemen NA* 45.03 (33.10-57.25) 1.63 (0.39-3.61) 1.61 (1.12-2.20) 25.09 (15.61-35.90) 10.32 (6.22-15.29)
Pooled estimates using all measures
Countries with a 
generalized 
epidemic‡
54.24 (37.67-70.34) 48.97 (43.68-54.27) 13.33 (11.62-15.14) 9.42 (8.96-9.88) 56.72 (51.45-61.91) 34.05 (27.10-41.35)
Countries with a 
concentrated 
epidemic§
48.14 (42.88-53.43) 26.38 (23.69-29.15) 4.14 (3.17-5.22) 0.60 (0.55-0.64) 15.55 (12.38-18.98) 7.36 (5.65-9.26)
All countries 49.06 (43.88-54.25) 30.10 (27.60-32.67) 6.59 (5.67-7.57) 2.44 (2.33-2.56) 34.75 (30.88-38.73) 15.63 (12.09-19.51)
Sensitivity analysis-Pooled estimates with population size weighting
Countries with a 
generalized 
epidemic‡
53.83 (37.27-69.97) 49.22 (44.09-54.36) 13.34 (11.74-15.02) 10.07 (9.66-10.49) 56.88 (51.66-62.03) 33.87 (26.70-41.44)
Countries with a 
concentrated 
epidemic§
48.21 (43.44-52.99) 26.19 (23.35-29.14) 4.06 (2.99-5.28) 0.73 (0.69-0.76) 15.50 (12.45-18.80) 7.03 (5.87-8.28)
All countries 49.04 (43.79-54.31) 30.11 (27.51-32.77) 6.58 (5.79-7.41) 2.89 (2.74-3.03) 34.79 (31.05-38.63) 15.40 (11.64-19.56)
*NA indicates that no estimates were available because no prevalence studies were identified.
†Point estimate for HCV prevalence based on a single study.
‡Classification based on the pooled mean HCV antibody prevalence in the general population being ≥3% (includes Egypt and Pakistan).
§Classification based on the pooled mean HCV antibody prevalence in the general population being <3% (includes all MENA countries 
other than Egypt and Pakistan).
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and for those with a concentrated epidemic, it was 
48.1%. For the MENA region as a whole, it was 
49.1%.
For populations with high-risk health care expo-
sures, the risk ranged between 7.4% in Lebanon and 
55.7% in Bahrain, with a median of 30.1%. The risk 
was 49.0% for countries with a generalized epidemic, 
26.4% for countries with a concentrated epidemic, 
and 30.1% for all the MENA countries.
For populations at intermediate risk, the risk was 
lower, ranging between 0.7% in Jordan and 15.7% in 
the UAE, with a median of 4.4%. The risk was 13.3% 
for countries with a generalized epidemic, 4.1% for 
countries with a concentrated epidemic, and 6.6% for 
all the MENA countries.
For general populations, the risk ranged between 
0.1% in Algeria and 11.8% in Egypt, with a median 
of 0.8%. The risk was 9.4% for countries with a gen-
eralized epidemic, only 0.6% for countries with a 
concentrated epidemic, and 2.4% for all the MENA 
countries.
For populations with liver conditions, the risk 
ranged between 0% in Djibouti and 58.8% in Egypt, 
with a median of 20.2%. The risk was 56.7% for coun-
tries with a generalized epidemic, 15.6% for countries 
with a concentrated epidemic, and 34.8% for all the 
MENA countries.
For special clinical populations, the risk ranged 
between 0% in Lebanon and 69.7% in Algeria, with 
a median of 10.5%. The risk was 34.1% for countries 
with a generalized epidemic, 7.4% for countries with a 
concentrated epidemic, and 15.6% for all the MENA 
countries.
Risk estimates for specific subpopulations by epi-
demic type and for all the MENA region are pre-
sented in Supporting Table S1.
RRs oF HaVing Been eXposeD
The pooled mean RRs of having been exposed to 
HCV infection are presented in Supporting Table S2 
for any two combinations of the population epidemi-
ologic categories. These pooled mean RRs are also 
shown in Fig. 2 relative to general populations for 
countries with a generalized epidemic (Fig. 2A), for 
countries with a concentrated epidemic (Fig. 2B), and 
for the MENA region as a whole (Fig. 2C).
Relative to general populations, for countries with 
a generalized epidemic, the pooled mean RR ranged 
between 1.6 for populations at intermediate risk and 
6.8 for PWID. For countries with a concentrated epi-
demic, the pooled mean RR ranged between 5.5 for 
populations at intermediate risk and 97.2 for PWID. 
For the MENA region as a whole, the pooled mean 
RR ranged between 4.8 for populations at intermedi-
ate risk and 62.5 for PWID.
yielDs oF a testing pRogRam
The yields in a testing program, i.e., the number of 
individuals needed to be tested to identify one chron-
ically infected individual, are presented in Table 3 
for each population epidemiologic category for each 
country. For PWID, the number needed to be tested 
to identify one case ranged from 1.4 in Libya to 5.3 
in Lebanon, with a median of 2.5. For countries with 
a generalized epidemic, it was 2.5, and for those with 
a concentrated epidemic, it was 2.8. For the MENA 
region as a whole, it was 2.7.
For populations with high-risk health care expo-
sures, the number needed to be tested ranged from 
2.4 in Bahrain and Egypt to 18.0 in Lebanon, with a 
median of 4.5. It was 2.7 for countries with a gener-
alized epidemic, 5.1 for countries with a concentrated 
epidemic, and 4.4 for all the MENA countries.
For populations at intermediate risk, the number 
that needed to be tested ranged from 8.5 in the UAE 
to 202.0 in Jordan, with a median of 30.6. It was 10.0 
for countries with a generalized epidemic, 32.2 for 
countries with a concentrated epidemic, and 20.2 for 
all the MENA countries.
For general populations, the number needed to 
be tested was higher, ranging from 11.3 in Egypt to 
1,025.6 in Algeria, with a median of 177.8. It was 
14.2 for countries with a generalized epidemic, 222.2 
for countries with a concentrated epidemic, and 54.6 
for all the MENA countries.
For populations with liver conditions, the num-
ber needed to be tested ranged from 2.3 in Egypt to 
128.2 in Syria, with a median of 6.3. It was 2.4 for 
countries with a generalized epidemic, 8.6 for coun-
tries with a concentrated epidemic, and 3.8 for all the 
MENA countries.
For special clinical populations, the number needed 
to be tested ranged from 1.9 in Algeria to 50.3 in 
Iran, with a median of 12.5. It was 3.9 for countries 
with a generalized epidemic, 18.1 for countries with 
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Fig. 2. Hierarchy of risk of exposure to the infection in MENA countries. (A) Pooled RR of having been exposed to HCV, relative 
to general populations, for the different population epidemiologic categories for countries with a generalized epidemic (Egypt and 
Pakistan). (B) Pooled RR relative to general populations but for countries with a concentrated epidemic. (C) Pooled RR relative to 
general populations for all countries.
Hepatology CommuniCations, Vol. 3, no. 3, 2019 CHemaitelly et al.
333
taBle 3. yielDs oF a testing pRogRam taRgeting populations at DiFFeRent RisKs oF 
Being eXposeD to HCV in mena CountRies
Country
Number of Individuals Needed to Be Tested to Identify One HCV Chronically Infected Individual (95% CI)
People Who 
Inject Drugs
Populations With 
High-Risk Health 
Care Exposures
Populations at 
Intermediate Risk
General 
Populations
Populations With 
Liver Conditions
Special Clinical 
Populations
Afghanistan 4.1 (3.2-5.3) NA* 57.0 (36.3-103.4) 180.2 (143.4-233.9) NA* NA*
Algeria NA* 7.5 (5.2-11.9) 26.9 (7.7- --†) 1025.6 
(459.8-4444.4)
NA* 1.9 (1.8-2.0)
Bahrain NA* 2.4 (1.6-5.1) NA* NA* NA* 16.3 (4.5- --†)
Djibouti NA* NA* NA* 476.2 (360.4-634.9) NA† NA*
Egypt 2.1 (1.8-2.5) 2.4 (2.2-2.7) 9.5 (7.3-13.2) 11.3 (10.6-12.0) 2.3 (2.0-2.6) 3.4 (2.9-4.1)
Iran 2.6 (2.3-2.8) 5.4 (4.5-6.5) 21.6 (13.9-38.8) 459.8 (360.4-634.9) 17.7 (11.7-30.7) 50.3 (36.9-73.3)
Iraq NA* 6.8 (5.4-8.8) 105.8 (67.3-196.1) 740.7 
(533.3-1,025.6)
19.1 (12.3-34.5) 48.1 (34.0-74.5)
Jordan NA* 4.0 (3.2-5.3) 202 (36.9-6,666.7) 888.9 
(533.3-1,904.8)
NA* 3.3 (2.7-4.1)
Kuwait NA* 7.1 (3.6-23.3) 25.0 (9.3-256.4) 97.3 (32.9-2,666.7) 22.7 (5.7- --†) 2.2 (1.7-3.2)
Lebanon 5.3 (2.4-30.3) 18.0 (11.7-32.1) 61.7 (24.9-512.8) 888.9 
(533.3-2,222.2)
6.8 (4.6-11.1) NA†
Libya 1.4 (1.4-1.5) 4.9 (3.6-7.1) 24.8 (12.4-76.6) 83.9 (75.8-92.6) NA* 3.5 (2.6-5.4)
Mauritania NA* NA* NA* 121.2 (45.8-430.1) NA* NA*
Morocco 2.5 (1.8-4.0) 3.5 (2.2-7.1) 34.4 (23.0-57.5) 205.1 (155.0-283.7) 3.5 (1.6-36.0) 14.8 (8.4-34.5)
Oman 2.8 (2.5-3.1) 4.0 (2.8-6.4) NA* 177.8 (144.9-222.2) NA* 15.2 (5.9-144.9)
Pakistan 2.5 (1.9-3.7) 4.1 (3.3-5.3) 10.3 (8.8-12.3) 21.7 (20.1-23.5) 2.4 (2.2-2.8) 5.4 (3.4-10.6)
Palestine 3.2 (2.8-3.7) 12.9 (8.2-23.6) NA* 555.6 (444.4-740.7) NA* NA*
Qatar NA* 3.0 (2.5-3.7) NA* 70.2 (45.5-122.3) 4.0 (2.7-7.2) 14.8 (8.1-31.8)
Saudi Arabia 2.3 (1.4-7.3) 2.9 (2.6-3.1) 14.9 (8.6-33.3) 177.8 (162.6-196.1) 4.9 (3.9-6.4) 11.9 (8.9-17.0)
Somalia NA* NA* 78.0 (29.2-1,333.3) 124.6 (62.0-416.7) 6.6 (3.1-29.5) NA*
Sudan NA* 7.2 (4.3-15.8) 190.5 (107.5-459.8) 98.0 (57.7-211.6) 18.2 (7.8-105.8) 25.6 (7.8- --†)
Syria 3.4 (1.7-19.0) 3.1 (2.2-5.1) 44.7 (30.0-75.3) 325.2 (283.7-370.4) 128.2 (36.1-1,025.6) 2.8 (1.9-4.8)
Tunisia 1.6 (1.5-1.7) 5.3 (4.4-6.6) 21.2 (9.3-101.8) 222.2 (168.8-303.0) 5.9 (3.5-13.3) 12.5 (4.3-476.2)
United Arab Emirates NA* 5.6 (4.4-6.9) 8.5 (3.9-37.2) 66.0 (45.0-106.7) NA* NA*
Yemen NA* 3.0 (2.3-4.0) 81.8 (36.9-341.9) 82.8 (60.6-119.0) 5.3 (3.7-8.5) 12.9 (8.7-21.4)
Yields of a testing programs based on pooling all measures
Countries with a 
generalized epidemic‡
2.5 (1.9-3.5) 2.7 (2.5-3.1) 10.0 (8.8-11.5) 14.2 (13.5-14.9) 2.4 (2.2-2.6) 3.9 (3.2-4.9)
Countries with a 
concentrated epidemic§
2.8 (2.5-3.1) 5.1 (4.6-5.6) 32.2 (25.5-42.1) 222.2 (208.3-242.4) 8.6 (7.0-10.8) 18.1 (14.4-23.6)
All countries 2.7 (2.5-3.0) 4.4 (4.1-4.8) 20.2 (17.6-23.5) 54.6 (52.1-57.2) 3.8 (3.4-4.3) 8.5 (6.8-11.0)
Sensitivity analysis-Yields of a testing program based on pooling all measures with population size weighting
Countries with a 
generalized epidemic‡
2.5 (1.9-3.6) 2.7 (2.5-3.0) 10.0 (8.9-11.4) 13.2 (12.7-13.8) 2.3 (2.1-2.6) 3.9 (3.2-5.0)
Countries with a 
concentrated epidemic§
2.8 (2.5-3.1) 5.1 (4.6-5.7) 32.8 (25.3-44.6) 182.6 (175.4-193.2) 8.6 (7.1-10.7) 19.0 (16.1-22.7)
All countries 2.7 (2.5-3.0) 4.4 (4.1-4.8) 20.3 (18.0-23.0) 46.1 (44.0-48.7) 3.8 (3.5-4.3) 8.7 (6.8-11.5)
The yield in a testing program is defined as the number of individuals needed to be tested to identify one HCV chronically infected 
individual.(28)
*NA indicates that no estimates were available because no prevalence studies were identified.
†Estimate could not be calculated as either HCV prevalence or the limit for its CI is 0 or too close to 0, indicating the need for an infi-
nite number of tests.
‡Classification based on the pooled mean HCV antibody prevalence in the general population being ≥3% (includes Egypt and Pakistan).
§Classification based on the pooled mean HCV antibody prevalence in the general population being <3% (includes all MENA countries 
other than Egypt and Pakistan).
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a concentrated epidemic, and 8.5 for all the MENA 
countries.
Yields of a testing program for specific subpopula-
tions by epidemic type and for the MENA region are 
presented in Supporting Table S1.
pRogRam eFFiCienCy anD 
testing pRogRam eXpansion 
patH CuRVes
The efficiency of the testing program is illustrated 
in Fig. 3. For countries with a generalized epidemic 
(Fig. 3A), the highest program efficiency was achieved 
by targeting populations with liver conditions, where 
only two individuals needed to be tested to identify 
one chronically infected individual. The expansion 
path curve was also largely flat by expanding the pro-
gram to include PWID, populations with high-risk 
health care exposures, and special clinical populations; 
only two to four tests would be needed to identify one 
chronic infection. However, the curve edged upward 
with expansion of the program to include popula-
tions at intermediate risk and general populations, 
indicating diminishing returns, although still only 10 
Fig. 3. Testing program expansion path curve in MENA countries. (A) Testing program expansion path curve for the yield, i.e., for 
the number of tests necessary to identify one HCV chronically infected individual for countries with a generalized epidemic (Egypt and 
Pakistan). (B) Testing program expansion path curve but for countries with a concentrated epidemic.
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to 15 tests would be needed to identify one chronic 
infection.
For countries with a concentrated epidemic (Fig. 
3B), the highest program efficiency was achieved by 
targeting PWID, where only three individuals needed 
to be tested to identify one chronically infected indi-
vidual. As the program was expanded to include pop-
ulations with high-risk health care exposures and 
populations with liver conditions, five and nine tests, 
respectively, would be needed to identify a chronic 
infection. As the program was expanded to more 
populations, the curve began a rapid climb upward, 
highlighting the diminishing returns of testing. Most 
notably, expansion of the program to general popula-
tions implied exponentially more tests (>200) to iden-
tify a single chronic infection.
sensitiVity analyses
Our estimates for the risk of having been exposed 
to HCV (Table 2), RRs of having been exposed to 
HCV infection (Supporting Table S3), and yields of a 
testing program (Table 3) were robust to data weight-
ing using country population size.
Only Egypt(7,66) and Pakistan(11,12) had HCV sero-
logic measures based on nationally representative pop-
ulation-based surveys. Pooled estimates for the risk of 
having been exposed to HCV using these data were 
8.0% (95% CI, 6.1-9.8) for Egypt and 4.9% (95% CI, 
4.7-5.1) for Pakistan. The corresponding numbers 
needed to be tested were 16.9 (95% CI, 13.6-21.7) 
for Egypt and 27.3 (95% CI, 26.3-28.5) for Pakistan. 
These estimates are similar to those generated using 
the totality of the evidence (Tables 2 and 3).
Discussion
Based on analyses of a massive and systematic data-
base of prevalence measures, we estimated the risk of 
exposure to HCV in the MENA region, quantified 
the yields of testing, and furnished a roadmap for effi-
ciently rolling out testing programs, all for the purpose 
of expanding treatment coverage. The results demon-
strated that major gains can be attained through a 
targeted approach that factors in epidemic type and 
is tailored to each country, thereby optimizing testing 
and treatment within budgetary constraints. Such a 
targeted approach has an additional indirect benefit 
of effectively curtailing transmission, as populations 
with a higher risk of exposure are also the same pop-
ulations that are more likely to pass the infection to 
uninfected persons. Although the analyses are specific 
to MENA countries, the results are probably general-
izable to other LMICs and regions with similar epi-
demic patterns.
These findings inform development of testing pro-
grams and policies at the country and regional levels, 
thereby attending to the first and fourth of the WHO’s 
GHSS strategic directions.(22,23) These call, respec-
tively, for characterizing populations at increased risk 
of exposure and for ensuring efficiency, cost-effective-
ness, and sustainability of programs.(4,22,23) With the 
constrained funding for HCV programming,(67-69) 
the financial implications of poorly informed testing 
strategies and inefficient testing campaigns may crip-
ple the political will to scale up test-and-treat pro-
grams, thus thwarting progress toward achieving the 
GHSS service coverage targets.(22,23,70) The presented 
results indicate a real opportunity for MENA coun-
tries to establish and/or optimize efficient test-and-
treat programs. Such programs would not only tackle 
existing infection and disease burden but also lead to 
a gradual decline in incidence, thus meeting GHSS 
targets and simultaneously achieving the 2030 elimi-
nation goal.(22,23,70)
Epidemiologically and for testing strategies, 
MENA countries clustered into two main patterns: 
generalized epidemics where HCV prevalence in 
the general population is ≥3% (Egypt and Pakistan) 
and concentrated epidemics where prevalence is 
<3% (remaining countries). In countries with gener-
alized epidemics (Table 2), the risk of having been 
exposed was high and similar for PWID, populations 
with liver conditions, and populations with high-risk 
health care exposures; in this last group, one in every 
two individuals is infected. This risk was also substan-
tial, although less than the former groups, for special 
clinical populations, populations at intermediate risk, 
and even general populations, signifying the terminol-
ogy of generalized epidemics.
Meanwhile, in countries with concentrated epi-
demics, there was a clear hierarchy in the risk of 
exposure (Table 2). PWID had the highest risk, 
followed by populations with high-risk health care 
exposures, populations with liver conditions, and spe-
cial clinical populations. The relative role of PWID 
was thus higher here than in generalized epidemics 
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(Table 2; Fig. 2A,B). The risk for populations at inter-
mediate risk and for general populations was very low 
(Table 2). Overall, risk estimates across countries were 
consistent and comparable with those of recent global 
reviews and estimations for the general population(5) 
(Supporting Table S4) and PWID(71) (although with 
some differences) for few countries with small epi-
demics and less data.
Remarkably, for both generalized and concentrated 
epidemics, the risk of exposure in clinical populations, 
including populations with high-risk health care 
exposures and special clinical populations, was sub-
stantial if not very high, indicating a critical role for 
health care in transmission. Although this important 
role for health care may not be well appreciated,(26,72) 
it demonstrates that any successful test-and-treat 
strategy (broadly in LMICs) needs to consider this 
reality of transmission in health care settings in HCV 
programming.
Targeted facility-based testing may be gradually 
introduced to identify clinical populations most at risk 
(such as dialysis or transfusion patients). Testing can 
later be extended to other clinical populations (such as 
hospital inpatients) as resources become available. Of 
note is that populations with liver conditions also had 
a high risk of exposure. Despite the variability in risk 
by epidemic type, this testifies to the role of HCV in 
liver disease in the MENA region.
A wide reaching general population testing policy 
in generalized epidemics is supported by the results 
(Table 3; Fig. 3A) because the number of tests needed 
to identify a chronic infection is low (<20). Such poli-
cies may include door-to-door community-based test-
ing,(73) routine testing in health services, and targeted 
testing for populations with high risk of exposure. 
However, in resource-constrained settings, a stepwise 
prioritization approach with targeted testing can still 
achieve higher program efficiency with the constraints 
in program resources.
Testing prioritization should be made with the aim 
of achieving the quickest public health gains in terms 
of achieving the elimination goal and thus should 
take into consideration testing efficiency based on the 
infection burden in specific population groups, the 
size of those population groups, and their contribu-
tion to the pool of infections within the country. For 
example, based on our findings, testing efficiency is 
highest if it targets, respectively, populations with liver 
conditions, PWID, and populations with high-risk 
health care exposures, where only two to four tests 
would be needed to identify a chronic infection, fol-
lowed by special clinical populations, populations at 
intermediate risk, and eventually general populations. 
However, realities on the ground, such as the size of 
the population of concern and its contribution to the 
overall pool of infection, may change the prioritiza-
tion order. Of note, challenges like ensuring adequate 
resources and necessary laboratory infrastructure to 
perform testing and linkage to treatment at the dis-
trict level should also be considered, even in the con-
text of generalized epidemics.
In concentrated epidemics, a targeted testing strat-
egy is critical for program efficiency (Table 3; Fig. 3B). 
Testing is most efficient by targeting PWID, followed 
by populations with high-risk health care exposures, 
populations with liver conditions, and lastly, special 
clinical populations. Given the large number of tests 
needed to identify a single chronic infection, it will be 
difficult to justify commitment of large resources for 
testing populations at intermediate risk and general 
populations. For instance, >200 tests would be needed 
to identify a single case in general populations. This 
being said, modeling studies could be used to assess 
the full impact of testing strategies on cost before a 
detailed policy is established.
The provided strategies for testing are based on an 
epidemiologic perspective. However, other consider-
ations can affect implementation of testing programs. 
Testing prioritization policies should follow treatment 
policies and take into consideration the availability of 
treatment for HCV. Testing strategies also need to 
factor in the ease of identifying populations at dif-
ferent risks of exposure as some populations may be 
difficult to identify and target. The size of each tar-
get population also needs to be considered. The size 
of the target population is an important factor; for 
instance, the size of PWID in a specific country may 
be too small relative to the overall size of the infected 
population, thereby affecting consideration, optimiza-
tion, and logistics of resource allocation.
Population accessibility is yet one more important 
factor. Accessing current PWID or ex-PWID may 
prove difficult.(47) Risk of reinfection is another fac-
tor, such as for PWID and populations with high-
risk health care exposures. With the recent increasing 
availability of generic DAA medicines in MENA 
countries at a cost below $100, such as in Egypt(18,19) 
and Pakistan,(20,21) which are the two most affected 
Hepatology CommuniCations, Vol. 3, no. 3, 2019 CHemaitelly et al.
337
countries, effort should be paid to prioritize and tar-
get testing and treatment based on the most efficient 
public health considerations, with a gradual scale-up 
to attain universal coverage of all population groups 
and elimination of HCV as an epidemic of public 
health concern. Cost-effectiveness is another consid-
eration, and this varies from one country to another 
based on actual costs of testing and treatment and 
the country-specific cost-effectiveness threshold as set 
based on the per-capita gross domestic product.(74,75)
Our analyses are limited by the variability in quan-
tity and quality of available data. For some countries, 
prevalence measures in some of the epidemiologic 
populations were not available or not sufficient to 
warrant estimations. On occasion, estimates were 
based on a small number of studies that may not have 
been representative of the considered population. We 
provided an analysis to inform testing with a focus 
on developing a regional strategy, but this may not be 
sufficient to devise a country-specific optimal strategy. 
The latter may need to incorporate additional data 
and contextual factors and be conducted as in-depth 
country-specific analyses that include all subpopula-
tions beyond the broad populations considered here. 
In the present study, however, the focus was on analy-
ses at the regional level and by epidemic type.
The effect of age, although important, also could 
not be assessed as age-stratified prevalence measures 
were not available for most countries. When avail-
able, these varied in how they were reported; different 
studies used different age group definitions, rendering 
a pooled analysis difficult. Another challenge was the 
variability in the affected age cohorts in one coun-
try to another given epidemic history, say in Egypt 
versus Pakistan.(11,13,50) Inclusion of age, thus, is best 
addressed through in-depth country-specific analyses, 
with the development of sensitive and specific risk 
scores being an additional aim.
The inverse variance weighting method was used 
when estimating pooled HCV prevalence. However, 
sensitivity analysis adding country population size 
for weighting data had no impact on our estimates 
for the pooled prevalence or related measures (yields 
of a testing program and RRs). Another method for 
weighting data, such as by time, could have also been 
considered. Yet, epidemic time-trend data were too 
limited for most countries to inform weighting that 
factors the epidemic’s temporal evolution. Overall, 
data were most complete only for Egypt and Pakistan, 
the two countries with generalized yet strikingly dif-
ferent epidemics.(50,54)
Our study has key strengths. The analyzed database 
is, to our knowledge, the largest and most compre-
hensive ever assembled of HCV prevalence measures. 
The database was built systematically and through 
standardized protocols and included all available prev-
alence measures in all populations in MENA coun-
tries. Such scope of epidemiologic evidence allowed 
extensive and stratified analyses that could not have 
been possible without such a database.
In conclusion, population risk of exposure depends 
on whether the type of epidemic is generalized or con-
centrated. Risk of exposure varies immensely by popu-
lation and shows a distinctive hierarchy in concentrated 
epidemics, but a less distinctive hierarchy in general-
ized epidemics. These findings indicate different test-
and-treat strategies by epidemic type. In all countries, 
however, testing strategy should be targeted with pri-
oritization determined by risk of exposure. Populations 
with liver conditions, clinical populations, and PWID 
should be at the core of every testing strategy. These 
findings inform the development of testing guidelines 
at the country and regional levels, thereby attending 
to the GHSS strategic directions to ensure program 
efficiency and sustainability of HCV programs.
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